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Abstract
A total of 3160 clinical isolates of Escherichia coli from intra-abdominal infections were collected during 2008–2009 from 13 European
countries. The frequency of extended-spectrum b-lactamase (ESBL)-producing isolates in Europe was 11%. The most active antibiotics
tested were typically imipenem, ertapenem, and amikacin, although the activity of all non-carbapenem antibiotics was lower when tested
against ESBL-positive isolates than when tested against ESBL-negative isolates. Ertapenem exhibited 99.3% susceptibility with all isolates,
and 96.8% susceptibility with ESBL-positive isolates. With application of the ertapenem CLSI clinical breakpoint for resistance
(MIC ‡1 mg/L), only six isolates (0.2%) were ertapenem-resistant, and only three of these were available for molecular characterization.
Of those three, only one was ESBL-positive (CTX-M-14), and two were carbapenemase-positive (OXA-48). All three were negative for,
VIM, NDM and KPC carbapenemases. Although the level of ertapenem resistance in E. coli is very low, further monitoring of ertapenem
susceptibility and molecular characterization of ertapenem-resistant isolates is needed.
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Introduction
Intra-abdominal infections (IAIs) represent some of the most
frequently encountered nosocomial infections in the
healthcare setting, and the majority are caused by Gram-neg-
ative bacilli (GNB) such as Escherichia coli, Klebsiella spp.,
Proteus spp., Enterobacter spp., Pseudomonas aeruginosa, and
Acinetobacter baumannii [1,2]. Failure of early diagnosis and
inadequate treatment of IAIs are suggested causes of clinical
failures, increased morbidity, and higher mortality rates
[3–7].
Antimicrobial agents or combinations of agents that are
currently recommended for the treatment of IAIs include
ampicillin–sulbactam, ertapenem, imipenem, meropenem,
piperacillin–tazobactam, cephalosporins used in combination
therapy, and quinolones, usually in combination with met-
ronidazole [8]. The Study for Monitoring Antimicrobial
Resistance Trends (SMART) monitors the susceptibility of
GNB from IAIs to ertapenem and comparators, and has
been ongoing since 2002, with nearly 170 hospitals partici-
pating worldwide as of 2009. Whereas ertapenem resis-
tance in other organisms, particularly Klebsiella pneumoniae,
appears to be more widely distributed, ertapenem resis-
tance in E. coli appears to have remained relatively low [9–
12]. However, metallo-b-lactamases and carbapenemases
have been indicated as impacting on the effectiveness
of carbapenem therapy [13–16]. This report from
SMART describes the susceptibility of E. coli isolated from
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Only one isolate per species per patient was accepted into
the study. Up to 100 consecutive non-selected Gram-nega-
tive aerobic and facultative anaerobic bacilli from each partic-
ipating hospital were cultured from specimens from
intra-abdominal body sites (e.g. appendix, peritoneum, colon,
bile, pelvis, and pancreas). The majority of IAI specimens
were obtained during surgery, although some paracentesis
specimens were also accepted. Isolates from blood, urine
and perirectal abscesses were excluded. Overall, 3160 iso-
lates of E. coli were collected in Europe from 44 hospitals
during 2008 and 2009 (France, 5; Germany, 6; Greece, 2;
Romania, 2; Spain, 11; Turkey, 3; Estonia, 2; Italy, 4; Latvia, 1;
Lithuania, 1; Portugal, 3; Switzerland, 1; UK, 3). Isolates were
identiﬁed to the species level at each site, and sent to a cen-
tral laboratory (Laboratories International for Microbiology
Studies, a subsidiary of International Health Management
Associates, Inc., Schaumburg, IL, USA) for conﬁrmation of
identiﬁcation and antimicrobial susceptibility testing. The
development of a centralized database of study results was
managed by International Health Management Associates,
Inc.. All organisms were deemed to be clinically signiﬁcant
according to local participant criteria. Isolate inclusion was
independent of antimicrobial use, age, or gender.
Susceptibility testing
MICs were determined with MicroScan dehydrated broth
microdilution panels (Siemens Medical Solutions Diagnostics,
West Sacramento, CA, USA), following CLSI guidelines [17].
The following antimicrobial agents were included on the pan-
els (dilution ranges are expressed in mg/L): ertapenem, 0.03–
4; imipenem, 0.06–8; cefepime, 0.5–32; ceftazidime, 0.5–128;
ceftazidime–clavulanic acid, 0.12/4–16/4; cefoxitin, 2–16; cip-
roﬂoxacin, 0.25–2; amikacin, 4–32; levoﬂoxacin, 0.5–4; cefo-
taxime, 0.5–128; cefotaxime–clavulanic acid, 0.12/4–16/4;
piperacillin–tazobactam, 2/4–64/4; ampicillin–sulbactam, 2/2–
16/2; and ceftriaxone, 1–32. MIC interpretive criteria for the
majority of antibiotics followed guidelines established by the
CLSI [18] and new clinical breakpoints published in 2010 for
carbapenems [19].
Extended-spectrum b-lactamase (ESBL) designation
With the use of CLSI guidelines, E. coli isolates were classi-
ﬁed as ESBL producers if there was at least an eight-fold
reduction (i.e. three doubling dilutions) in the MIC of ceftazi-
dime or cefotaxime tested in combination with clavulanic
acid vs. their MICs when tested alone [17].
Molecular characterization
DNA was extracted from overnight colonies grown on
blood agar (Remel, Lenexa, KS, USA) with the QIAamp
DNA Mini Kit and the QIAcube instrument (Qiagen, Valen-
cia, CA, USA). PCR for characterization of ESBLs was per-
formed in an ABI 9700 thermocycler (Applied Biosystems,
Carlsbad, CA, USA). TEM, SHV, CTX-M, OXA-48, metallo-
enzymes (VIM, and NDM) and KPC-type enzymes were
ampliﬁed as previously described [20–24]. PCR was carried
out with the Fast Cycling PCR Kit (Qiagen). Puriﬁcation of
the PCR products was performed with Exo-SAP-IT (USB,
Cleveland, OH, USA). PCR-ampliﬁed fragments were
sequenced with the ABI 3730XL DNA analyser (Applied Bio-
systems). Nucleotide sequences were analysed with SeqScape
v. 7.0 (Applied Biosystems), and compared with sequences
available on the Internet at the National Center for Biotech-
nology Information website (http://www.ncbi.nlm.nih.gov).
Multiplex ampliﬁcation of the pAmpC genes was performed
as previously described by Perez-Perez and Hanson [25].
Quality control
Quality control (QC) testing was performed each day
of testing with the CLSI-recommended QC strains:
E. coli ATCC 25922, E. coli ATCC 35218, P. aeruginosa
ATCC 27853, and K. pneumoniae ATCC 700603 (positive
ESBL control). Results were included in the analysis only
when corresponding QC isolates tested within the accept-
able range according to CLSI guidelines [18].
Results
Table 1 shows the distribution of the 3160 clinical isolates by
geographical region, ESBL status, number of hospital sites, and
incidence of ertapenem-resistant isolates. Hospital sites per
country ranged from one (Latvia, Lithuania, and Switzerland)
to 11 (Spain). Among the total of 44 sites within Europe, an
average of 72 clinical isolates were collected per site. Exclud-
ing Switzerland, from which only four isolates were collected,
numbers of isolates per site ranged from 34 (Romania) to 104
(Latvia and Spain). A total of 11% of isolates were ESBL-posi-
tive. Excluding Switzerland, owing to the very small number,
ESBL rates ranged from 1.4% (Estonia) to 35% (Turkey). Of
the 3160 isolates collected throughout Europe, only six
(0.2%) were ertapenem-resistant (MIC ‡1 mg/L). Ertapenem
resistance was detected in only four of the 13 European
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countries; in those four countries, resistance rates ranged
from 0.09% in Spain to 1.0% in Turkey.
Table 2 describes the activity of ertapenem and compara-
tors against all isolates, ESBL-positive isolates and ESBL-nega-
tive isolates from Europe as a region. Against all isolates
(n = 3160), the most active agents were imipenem, ertape-
nem, and amikacin, with susceptibilities of 99.7%, 99.3%, and
98.2%, respectively. Against ESBL-positive isolates (n = 349),
the most active agents were imipenem and ertapenem, with
susceptibilities of 100% and 96.8%, respectively. All other
agents exhibited reduced susceptibilities, including amikacin,
which exhibited a susceptibility of 88%. ESBL-negative iso-
lates were generally susceptible to all agents, with only ampi-
cillin–sulbactam (49.2% susceptible), levoﬂoxacin (83.0%
susceptible) and ciproﬂoxacin (82.4% susceptible) exhibiting
susceptibility percentages <90% (Table 2).
TABLE 1. Distribution of 3160
clinical isolates of Escherichia coli
by country, extended-spectrum
b-lactamase (ESBL) frequency, and
ertapenem resistance
Country Sites N Average N/site % ESBL+ N EPMR % EPMR
Estonia 2 70 35 1.4 0 0
France 5 401 80 6.5 1 0.3
Germany 6 346 58 11.3 1 0.3
Greece 2 90 45 18.9 1 1.1
Italy 4 303 76 14.2 0 0
Latvia 1 104 104 9.6 0 0
Lithuania 1 102 102 2.9 0 0
Portugal 3 218 73 12.8 0 0
Romania 2 67 34 10.5 0 0
Spain 11 1142 104 8 1 0.09
Switzerland 1 4 4 0 0 0
Turkey 3 194 65 35 2 1.0
UK 3 119 40 13.4 0 0
Europe 44 3160 72 11 6 0.2
N, total number of isolates collected; Average N/site, mean number of isolates per site; N EPMR, number of ertape-
nem-resistant isolates; % EPMR, percentage of ertapenem-resistant isolates.
TABLE 2. Susceptibility of Escheri-
chia coli isolates from Europe to
ertapenem and comparators
Drug MIC50 (mg/L) MIC90 (mg/L) %S %I %R
All (n = 3160)
Amikacin £4 8 98.2 1.1 0.7
Ampicillin–sulbactam 16 >16 44.4 21.0 34.6
Cefepime £0.5 4 90.8 0.4 8.8
Cefotaxime £0.5 64 86.6 0.6 12.8
Cefoxitin £2 8 93.5 3.5 3.0
Ceftazidime £0.5 4 90.3 1.3 8.4
Ceftriaxone £1 >32 86.7 0.5 12.8
Ciproﬂoxacin £0.25 >2 76.1 0.3 23.6
Ertapenem £0.03 £0.03 99.3 0.5 0.2
Imipenem 0.12 0.25 99.7 0.2 0.1
Levoﬂoxacin £0.5 >4 76.7 2.3 21.0
Piperacillin–tazobactam £2 16 91.4 3.6 5.0
ESBL-positive (n = 349)
Amikacin 8 32 88.0 8.6 3.4
Ampicillin–sulbactam >16 >16 6.6 22.4 71.1
Cefepime >32 >32 19.5 2.9 77.7
Cefotaxime >128 >128 2.9 0.6 96.6
Ceftazidime 32 >128 31.8 5.4 62.8
Cefoxitin 4 16 86.2 11.2 2.6
Ceftriaxone >32 >32 3.4 0.0 96.6
Ciproﬂoxacin >2 >2 25.8 0.3 73.9
Ertapenem £0.03 0.12 96.8 2.9 0.3
Imipenem 0.12 0.25 100.0 0.0 0.0
Levoﬂoxacin >4 >4 26.1 4.0 69.9
Piperacillin–tazobactam 8 >64 77.6 11.5 10.9
ESBL-negative (n = 2811)
Amikacin £4 8 99.5 0.2 0.3
Ampicillin–sulbactam 16 >16 49.2 20.8 30.0
Cefepime £0.5 £0.5 99.6 0.1 0.2
Cefotaxime £0.5 £0.5 97.0 0.6 2.3
Cefoxitin £2 8 94.4 2.6 3.0
Ceftazidime £0.5 £0.5 97.5 0.8 1.7
Ceftriaxone £1 £1 97.2 0.5 2.3
Ciproﬂoxacin £0.25 >2 82.4 0.3 17.3
Ertapenem £0.03 £0.03 99.7 0.2 0.1
Imipenem 0.12 0.25 99.6 0.2 0.2
Levoﬂoxacin £0.5 >4 83.0 2.1 15.0
Piperacillin–tazobactam £2 8 93.1 2.6 4.3
ESBL, extended-spectrum b-lactamase; %S, %I, and %R, percentages of isolates susceptible, intermediate, or resistant,
respectively..
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Susceptibility to ertapenem varied little between countries.
For all isolates (3160), the ertapenem average susceptibility
rate in Europe was 99.3%, with minimum and maximum sus-
ceptibilities of 96.9% in Turkey and 100% in Estonia, Latvia,
Lithuania, Portugal, Romania, and Switzerland (Table 3). For
ESBL-positive isolates (n = 349), the ertapenem susceptibility
rate in Europe overall was 96.8%, with minimum and maximum
susceptibilities of 90.7% in Italy and 100% in Estonia, Germany,
Latvia, Lithuania, Portugal, and Romania. For ESBL-negative
isolates (n = 2811), the ertapenem susceptibility rate in
Europe overall was 99.7%, with 100% of isolates being suscep-
tible in Estonia, Germany, Latvia, Lithuania, Portugal, Romania,
Switzerland, and the UK, and ‡97.6% being susceptible in all
other sites (Table 3). None of the percentage susceptibility
rates observed deviated signiﬁcantly from the average for the
region (p >0.05).
Only a very small proportion of isolates exhibited resis-
tance to ertapenem. Of the total of 3160 isolates, only six
(0.2%) exhibited resistance to ertapenem. Of these, three
were imipenem-susceptible. In the recently updated CLSI
guidelines [19], ertapenem resistance in Enterobacteriaceae is
deﬁned as an MIC of ‡1 mg/L. As part of this study, a
subgroup including both ertapenem-susceptible and ertape-
nem-resistant isolates was characterized to determine the
molecular mechanisms of resistance. Of the six ertapenem-
resistant isolates, three were further characterized with
molecular methodologies in order to detect the presence
of the genes encoding CTX-M, SHV, TEM, AmpC, KPC,
OXA, and VIM. Three of the six isolates were unavailable
for molecular characterization. Of the isolates, only one
was identiﬁed by MIC as being phenotypically ESBL-positive
according to CLSI guidelines. The isolate was from France,
was isolated in 2008 from peritoneal ﬂuid, exhibited an er-
tapenem MIC of 2 mg/L, and was positive for CTX-M-14
but negative for AmpC, SHV, TEM, KPC, OXA, and VIM.
The other two isolates from Turkey were ESBL-negative by
TABLE 3. Susceptibility to ertape-
nem of Escherichia coli from 13
European countries
Country N MIC50 (mg/L) MIC90 (mg/L) %S %I %R
All (n = 3160)
Estonia 70 £0.03 £0.03 100 0.0 0.0
France 401 £0.03 £0.03 99.5 0.3 0.2
Germany 346 £0.03 £0.03 99.7 0.0 0.3
Greece 90 £0.03 £0.03 97.8 2.2 0.0
Italy 303 £0.03 0.06 98.4 1.7 0.0
Latvia 104 £0.03 £0.03 100 0.0 0.0
Lithuania 102 £0.03 £0.03 100 0.0 0.0
Portugal 218 £0.03 £0.03 100 0.0 0.0
Romania 67 £0.03 £0.03 100 0.0 0.0
Spain 1142 £0.03 £0.03 99.9 0.2 0.01
Switzerland 4 £0.03 £0.03 100 0.0 0.0
Turkey 194 £0.03 0.12 96.9 2.1 1.0
UK 119 £0.03 £0.03 99.2 0.8 0.0
Europe 3160 £0.03 £0.03 99.3 0.5 0.2
ESBL-positive (n = 349)
Estonia 1 £0.03 £0.03 100 0.0 0.0
France 26 £0.03 0.12 96.2 0.0 3.9
Germany 39 £0.03 0.12 100 0.0 0.0
Greece 17 £0.03 0.12 94.1 5.9 0.0
Italy 43 0.06 0.25 90.7 9.3 0.0
Latvia 10 £0.03 0.06 100 0.0 0.0
Lithuania 3 0.06 0.06 100 0.0 0.0
Portugal 28 0.06 0.12 100 0.0 0.0
Romania 7 £0.03 0.12 100 0.0 0.0
Spain 91 £0.03 0.06 98.9 1.1 0.0
Turkey 68 £0.03 0.25 95.6 4.4 0.0
UK 16 £0.03 0.25 93.8 6.3 0.0
Europe 349 £0.03 0.12 96.8 2.9 0.3
ESBL-negative (n = 2811)
Estonia 69 £0.03 £0.03 100 0.0 0.0
France 375 £0.03 £0.03 99.7 0.3 0.0
Germany 307 £0.03 £0.03 100 0.0 0.0
Greece 73 £0.03 £0.03 98.6 1.4 0.0
Italy 260 £0.03 £0.03 99.6 0.4 0.0
Latvia 94 £0.03 £0.03 100 0.0 0.0
Lithuania 99 £0.03 £0.03 100 0.0 0.0
Portugal 190 £0.03 £0.03 100 0.0 0.0
Romania 60 £0.03 £0.03 100 0.0 0.0
Spain 1051 £0.03 £0.03 99.9 0.1 0.0
Switzerland 4 £0.03 £0.03 100 0.0 0.0
Turkey 126 £0.03 £0.03 97.6 0.8 1.6
UK 103 £0.03 £0.03 100 0.0 0.0
Europe 2811 £0.03 £0.03 99.7 0.2 0.1
ESBL, extended-spectrum b-lactamase; %S, %I, and %R, percentages of isolates susceptible, intermediate, or resistant,
respectively.
256 Clinical Microbiology and Infection, Volume 18 Number 3, March 2012 CMI
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, 253–259
phenotype and genotype, although were both OXA-48-
positive.
Discussion
Previous SMART reports have consistently shown that E. coli
isolates from IAIs are highly susceptible to ertapenem, imipe-
nem, and amikacin. The susceptibility of ESBL-positive
isolates to the carbapenems has consistently been >95%
[26–29]. The present study reports similar ﬁndings for E. coli
isolated from various types of IAI from Europe during 2008–
2009, with superior in vitro activity being observed for the
carbapenems against all E. coli phenotypes.
Prior to January 2010, the CLSI ertapenem clinical break-
points for E. coli were £2, 4 and ‡8 mg/L for susceptible,
intermediate and resistant, respectively [18]. However, in
June 2010, the CLSI updated clinical breakpoints for carba-
penems to better differentiate wild-type from resistant popu-
lations, especially with respect to carbapenemase producers,
and to better reﬂect the pharmacokinetic/pharmacodynamic
parameters of the drugs [19]. The resultant lower clinical
breakpoints for ertapenem represent a change of several
MIC dilutions, and currently stand as £0.25, 0.5 and ‡1 mg/L
for susceptible, intermediate and resistant, respectively. All
analyses performed in the present report used the CLSI
M100-S20-U breakpoints published in June 2010 [19]. Not-
withstanding the signiﬁcantly lower ertapenem breakpoints,
resistance to ertapenem in this study was very low, being
only 0.2% in Europe as a whole. Resistance was highest in
Turkey (two ertapenem-resistant isolates; resistance rate,
1.0%), and was completely absent in nine of the 13 countries
studied (Estonia, Greece, Italy, Latvia, Lithuania, Portugal,
Romania, Switzerland, and the UK).
Carbapenem resistance in various GNB has been effec-
tively demonstrated to be linked to the presence of a variety
of molecular mechanisms, including CTX-M ESBL, OXA-48
carbapenemase, VIM carbapenemase, SHV, KPC, and altered
permeability [16,21,30–38]. In ESBL-positive organisms, the
role of CTX-M-15, among others, has been well documented
[34]. Recently, carbapenem resistance has been increasingly
linked to the combination of ESBLs with alterations in cell
wall permeability, with isolates having altered OmpK35 and
OmpK36 expression [31,33]. Although OMP analyses were
not performed as part of the present study, it seems likely
that the single ertapenem-resistant ESBL-positive isolate has
an OMP deﬁciency, as has been described elsewhere, indicat-
ing that the combination of an ESBL with OMP deﬁciency
can confer resistance to carbapenems [22]. The other two
ertapenem-resistant isolates from Turkey were shown to
produce OXA-48 enzymes, but, interestingly, were both sus-
ceptible to imipenem, suggesting only very weak carbape-
nemase production. OXA-48 is emerging in E. coli, and has
been observed in isolates from Lebanon, Egypt, France,
Israel, and Belgium [39], so close monitoring of the dissemi-
nation of OXA-48-positive E. coli isolates in Europe is
warranted.
In the present study, resistance to other antimicrobial
agents, especially the cephalosporins and the quinolones, was
high. Furthermore, whereas ESBL-negative isolates exhibited
>80% susceptibility to all agents tested, with the exception of
ampicillin–sulbactam (49.2% susceptible), ESBL-positive iso-
lates were highly resistant to the majority of agents. For
example, ciproﬂoxacin and levoﬂoxacin resistance rates were
73.9% and 69.9%, respectively, in ESBL-positive isolates. These
ﬁndings are similar to those shown elsewhere [26–29].
It is encouraging that data from the present study show
that resistance to carbapenems in European E. coli isolates
from IAIs remains very low, in contrast to reports of
increasing carbapenem resistance in K. pneumoniae, mostly
attributable to the emergence of KPC-producing isolates
[14]. Similar resistance trends in E. coli have not yet
emerged, despite carbapenems having been in clinical use for
many years. Surveillance programmes such as SMART will
continue to play key roles in detecting and monitoring any
change in carbapenem resistance, locally, regionally, and glob-
ally, in E. coli from IAIs.
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